A major outcome of the British Pharmacological Society’s ‘Focus on Pharmacology’ project has been a 2016 review of the Integrative Pharmacology Fund (IPF), a shared venture with AstraZeneca, GlaxoSmithKline, Pfizer, public funders and the Society to help support in vivo knowledge and skills. The impact of the £22m fund over its 12-year lifetime was evaluated and recommendations made for in vivo education, research and training. Drawing upon expertise from across the in vivo community, the Society and The Physiological Society co-hosted a workshop in November 2017 to discuss how these recommendations might be implemented. Future challenges arising from a changing scientific landscape were discussed as well as how best to nurture networks of good practice. Going forward, we will condense the outputs of these discussions and produce a report that will inform the necessary next steps for the in vivo community to ensure a sustainable and well-rounded future in vivo landscape.